Is Knight Therapeutics Inc. (KHTRF) a Buy, Sell, or Hold?
OTC : KHTRF
Knight Therapeutics Inc. — News
$6.85 USD
-$0.09 (-1.3%)
- Volume
- 200
- Average Volume
- 6.07K
- Market Capitalization
- $672.53M
- P/E Ratio
- 64.58
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $7.40
- Year Low
- $4.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.28
| Source | Headline |
|---|---|
|
Knight Therapeutics Q2 Earnings Call Highlights
Knight Therapeutics TSE: GUD reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and favorable foreign-exchange effects. marketbeat.com - 2026-08-09 20:04:50 |
|
Knight Therapeutics Announces Repayment of Revolving Credit Facility
MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders. globenewswire.com - 2026-06-17 17:30:00 |
|
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1 globenewswire.com - 2026-05-27 18:00:00 |
